Read on Twitter
DCGI has granted permission for emergency use of drug 2-deoxy-D-glucose (2-DG) as adjunct therapy in moderate to severe COVID-19 patients.
"A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SOC", according to DRDO.
I could find an article in pubmed published last year titled,
"A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management" https://pubmed.ncbi.nlm.nih.gov/32910699/
"A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management" https://pubmed.ncbi.nlm.nih.gov/32910699/
"Due to its polypharmacological effects, mainly comprising inhibition of glycolysis,
modulation of inflammatory responses (cytokine storm) & alterations in glycosylation of viral proteins, 2-DG will be
effective in inhibiting viral replication & preventing lung damage."
modulation of inflammatory responses (cytokine storm) & alterations in glycosylation of viral proteins, 2-DG will be
effective in inhibiting viral replication & preventing lung damage."
"However, the dose of 2-DG required
and daily administration needed may cause concern regarding non-target effects in the form of CNS disturbances and
cardio-respiratory disturbances"
and daily administration needed may cause concern regarding non-target effects in the form of CNS disturbances and
cardio-respiratory disturbances"
